Market Overview

UPDATE: Stifel Nicolaus Downgrades Zogenix to Hold Following FDA Panel

Share:
Related ZGNX
22 Stocks To Watch After President Trump Declares Opioid Epidemic A National Health Emergency
Benzinga's Option Alert Recap From October 13

Stifel Nicolaus reduced its rating on Zogenix (NASDAQ: ZGNX) from Buy to Hold and removed its $6 price target.

Stifel Nicolaus said, "The FDA Advisory Committee for Zohydro ER (single-entity hydrocodone for moderate-severe chronic pain) voted 11-2 (one abstention) against approval, highlighting concern about the opioid abuse epidemic by adding yet another non tamper-resistant, high-dose opioid. … [I]ncomplete information about how to limit the addressable population, concern regarding REMS implementation, and lack of tamper-resistance were key sticking points. Although FDA may still approve Zohydro given its legal/regulatory mandate (PDUFA 3/1/13), we are downgrading Zogenix given increased risk on its key growth driver."

Zogenix closed at $2.36 on Friday.

Latest Ratings for ZGNX

DateFirmActionFromTo
Oct 2017Leerink SwannMaintainsOutperformOutperform
Sep 2017MizuhoInitiates Coverage OnBuy
Nov 2016Aegis CapitalInitiates Coverage OnBuy

View More Analyst Ratings for ZGNX
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Downgrades Intraday Update Analyst Ratings

 

Related Articles (ZGNX)

View Comments and Join the Discussion!

Partner Center